| Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other diseases. The U.S. Food and Drug Administration (FDA) granted approval of TAZVERIK (tazemetostat) for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase that Co. is developing. The FDA has also granted orphan drug designation to tazemetostat for the treatment of patients with follicular lymphoma, malignant rhabdoid tumors, soft tissue sarcoma, and mesothelioma. We show 29 historical shares outstanding datapoints in our EPZM shares outstanding history coverage, used to compute EPZM market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EPZM market cap history over the course of time is important for investors
interested in comparing EPZM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EPZM versus a peer is one thing; comparing
EPZM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EPZM can fluctuate over the course of history.
With this page we aim to empower investors researching EPZM by allowing them to research the EPZM market cap history.